Related Experiment Video

Updated: May 13, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Isocitrate lyase: a potential target for anti-tubercular drugs

Rohit Sharma1, Oisik Das, Satyawan G Damle

  • 1Department of Biotechnology, Maharishi Markandeshwar University, Mullana-Ambala-133207, India.

Recent Patents on Inflammation & Allergy Drug Discovery
|March 20, 2013
PubMed

Insights

New anti-tuberculosis drugs targeting isocitrate lyase (ICL) are crucial for combating resistant strains. Research highlights ICL as a promising target, with several compounds showing significant antimycobacterial activity.

Area of Science:

  • Microbiology
  • Medicinal Chemistry
  • Drug Discovery

Background:

  • Current tuberculosis (TB) treatments rely on drugs targeting limited metabolic pathways, leading to resistance.
  • Novel drug targets are urgently needed to overcome mutation resistance in Mycobacterium tuberculosis.
  • The glyoxylate cycle enzyme, isocitrate lyase (ICL), is vital for M. tuberculosis persistence.

Purpose of the Study:

  • To review the therapeutic potential of isocitrate lyase (ICL) as a novel drug target for tuberculosis.
  • To discuss recent advancements and patents related to ICL-targeted anti-tubercular drug development.

Main Methods:

  • Literature review of studies investigating isocitrate lyase (ICL) as a drug target.
  • Analysis of synthesized compounds with potential antimycobacterial activity against ICL.
  • Review of relevant patents in the field of ICL research for tuberculosis.

Main Results:

  • Isocitrate lyase (ICL) plays a critical role in the persistence of Mycobacterium tuberculosis.
  • Several compound classes, including salicylanilides and benzanilides, demonstrate potential to inhibit mycobacterial ICL.
  • Synthesized compounds exhibit significant antimycobacterial effects, indicating therapeutic promise.

Conclusions:

  • Isocitrate lyase (ICL) represents a viable and important novel drug target for developing new anti-tubercular therapies.
  • Further investigation into ICL inhibitors is warranted to develop effective treatments against drug-resistant tuberculosis.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...